Re: "No Significant Changes in Weight and Body Fat Mass in Suppressed HIV Infected Patients Switched to Dual Combination Lamivudine plus Dolutegravir or Raltegravir" by Calza et al

A. Ciccullo; G. Baldin; V. Borghi; A. P. Lassandro; D. Farinacci; G. Guaraldi; C. Mussini; Simona Di Giambenedetto

doi:10.1089/aid.2020.0274

Re: "No Significant Changes in Weight and Body Fat Mass in Suppressed HIV Infected Patients Switched to Dual Combination Lamivudine plus Dolutegravir or Raltegravir" by Calza et al

A. Ciccullo^*
, G. Baldin
, V. Borghi
, A. P. Lassandro
, D. Farinacci
, G. Guaraldi
, C. Mussini
, Simona Di Giambenedetto

^*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivista › Articolo

Abstract

N/A Not Available

Lingua originale	Inglese
pagine (da-a)	333-334
Numero di pagine	2
Rivista	AIDS Research and Human Retroviruses
Volume	37
Numero di pubblicazione	5
DOI	https://doi.org/10.1089/aid.2020.0274
Stato di pubblicazione	Pubblicato - 2021

All Science Journal Classification (ASJC) codes

Immunologia
Virologia
Malattie Infettive

Keywords

3-Ring
Adipose Tissue
Anti-HIV Agents
HIV Infections
Heterocyclic Compounds
Humans
Lamivudine
Oxazines
Piperazines
Pyridones
Raltegravir Potassium

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1089/aid.2020.0274

Altri file e collegamenti

Cita questo

Ciccullo, A., Baldin, G., Borghi, V., Lassandro, A. P., Farinacci, D., Guaraldi, G., Mussini, C., & Di Giambenedetto, S. (2021). Re: "No Significant Changes in Weight and Body Fat Mass in Suppressed HIV Infected Patients Switched to Dual Combination Lamivudine plus Dolutegravir or Raltegravir" by Calza et al. AIDS Research and Human Retroviruses, 37(5), 333-334. https://doi.org/10.1089/aid.2020.0274

@article{209d7a6868a542f9b51b6059af57e069,

title = "Re: {"}No Significant Changes in Weight and Body Fat Mass in Suppressed HIV Infected Patients Switched to Dual Combination Lamivudine plus Dolutegravir or Raltegravir{"} by Calza et al",

abstract = "N/A Not Available",

keywords = "3-Ring, Adipose Tissue, Anti-HIV Agents, HIV Infections, Heterocyclic Compounds, Humans, Lamivudine, Oxazines, Piperazines, Pyridones, Raltegravir Potassium, 3-Ring, Adipose Tissue, Anti-HIV Agents, HIV Infections, Heterocyclic Compounds, Humans, Lamivudine, Oxazines, Piperazines, Pyridones, Raltegravir Potassium",

author = "A. Ciccullo and G. Baldin and V. Borghi and Lassandro, \{A. P.\} and D. Farinacci and G. Guaraldi and C. Mussini and \{Di Giambenedetto\}, Simona",

year = "2021",

doi = "10.1089/aid.2020.0274",

language = "English",

volume = "37",

pages = "333--334",

journal = "AIDS Research and Human Retroviruses",

issn = "0889-2229",

publisher = "Mary Ann Liebert Inc.",

number = "5",

}

Ciccullo, A, Baldin, G, Borghi, V, Lassandro, AP, Farinacci, D, Guaraldi, G, Mussini, C & Di Giambenedetto, S 2021, 'Re: "No Significant Changes in Weight and Body Fat Mass in Suppressed HIV Infected Patients Switched to Dual Combination Lamivudine plus Dolutegravir or Raltegravir" by Calza et al', AIDS Research and Human Retroviruses, vol. 37, n. 5, pagg. 333-334. https://doi.org/10.1089/aid.2020.0274

TY - JOUR

T1 - Re: "No Significant Changes in Weight and Body Fat Mass in Suppressed HIV Infected Patients Switched to Dual Combination Lamivudine plus Dolutegravir or Raltegravir" by Calza et al

AU - Ciccullo, A.

AU - Baldin, G.

AU - Borghi, V.

AU - Lassandro, A. P.

AU - Farinacci, D.

AU - Guaraldi, G.

AU - Mussini, C.

AU - Di Giambenedetto, Simona

PY - 2021

Y1 - 2021

N2 - N/A Not Available

AB - N/A Not Available

KW - 3-Ring

KW - Adipose Tissue

KW - Anti-HIV Agents

KW - HIV Infections

KW - Heterocyclic Compounds

KW - Humans

KW - Lamivudine

KW - Oxazines

KW - Piperazines

KW - Pyridones

KW - Raltegravir Potassium

KW - 3-Ring

KW - Adipose Tissue

KW - Anti-HIV Agents

KW - HIV Infections

KW - Heterocyclic Compounds

KW - Humans

KW - Lamivudine

KW - Oxazines

KW - Piperazines

KW - Pyridones

KW - Raltegravir Potassium

UR - https://publicatt.unicatt.it/handle/10807/193264

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85105730670&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85105730670&origin=inward

U2 - 10.1089/aid.2020.0274

DO - 10.1089/aid.2020.0274

M3 - Article

SN - 0889-2229

VL - 37

SP - 333

EP - 334

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

IS - 5

ER -

Re: "No Significant Changes in Weight and Body Fat Mass in Suppressed HIV Infected Patients Switched to Dual Combination Lamivudine plus Dolutegravir or Raltegravir" by Calza et al

Abstract

All Science Journal Classification (ASJC) codes

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo